Efficacy News and Research

RSS
Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Cell Medica signs R&D agreement with the Center for Cell and Gene Therapy

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

Heart Force Medical closes its private, non-brokered financing after raising $4.8 million net

Heart Force Medical closes its private, non-brokered financing after raising $4.8 million net

Positive top-line results from Phase III study of aclidinium bromide announced

Positive top-line results from Phase III study of aclidinium bromide announced

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

New tools show potential for treating brain disorders

New tools show potential for treating brain disorders

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Ensemble Discovery initiates strategic alliance with Pfizer

Ensemble Discovery initiates strategic alliance with Pfizer

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

More research needed to assess psychological debriefing in schools

More research needed to assess psychological debriefing in schools

Innexus Biotechnology designs new psoriasis product

Innexus Biotechnology designs new psoriasis product

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

Keryx Biopharmaceuticals reaches SPA agreement for Phase 3 clinical program for Zerenex

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Phase I clinical trial for Intellikine's INK128 inhibitor initiated

Scott & White's CRI launches two clinical trials targeting cancers

Scott & White's CRI launches two clinical trials targeting cancers

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

EnVivo Pharmaceuticals announces initiation and dosing of patients in Phase 2b study of EVP-6124

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.